Immune response of patients with rheumatoid arthritis during cyclophosphamide treatment.
D000917:Antibody Formation / Q000187:drug effects*; D000941:Antigens; D001172:Arthritis, Rheumatoid / Q000276:immunology*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular / Q000187:drug effects*; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008213:Lymphocyte Activation; D010919:Placebos; D012882:Skin Tests
D000941:Antigens; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010919:Placebos; D003520:Cyclophosphamide